La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Coeur D'Alene Bancorp a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Coeur D'Alene Bancorp..

Coeur D'Alene Bancorp (OTC:CDAB) Azioni, Catena delle Opzioni

Coeur D'Alene Bancorp is a holding company for banks. It provides a full range of banking services to its commercial and consumer customers through its four branches serving Coeur d'Alene, Post Falls, Hayden, Kellogg, Idaho, and contiguous areas. It offers Business loans and Personal loans, home loans including consumer loans and construction loans, and also offers e-banking services including online banking, bill pay, mobile banking, and online education.

COEUR D ALENE BANCORP by Coeur D Alene Bancorp

Coeur D'Alene Bancorp

Whales with a lot of money to spend have taken a noticeably bullish stance on Verona Pharma.
Looking at options history for Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 64% of the investors opened trades with bullish expectations and 28% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $319,653 and 7, calls, for a total amount of $262,865.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $45.0 to $60.0 for Verona Pharma during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Verona Pharma's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Verona Pharma's significant trades, within a strike price range of $45.0 to $60.0, over the past month.
<h3>Verona Pharma Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054978_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$55.00</td>
<td>$75.1K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.3</td>
<td>$55.00</td>
<td>$68.3K</td>
<td>0</td>
<td>715</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.4</td>
<td>$5.1</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$56.9K</td>
<td>2.3K</td>
<td>80</td>
</tr>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$55.00</td>
<td>$46.5K</td>
<td>0</td>
<td>420</td>
</tr>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.1</td>
<td>$5.2</td>
<td>$5.1</td>
<td>$55.00</td>
<td>$41.8K</td>
<td>0</td>
<td>82</td>
</tr>
</tbody>
</table>

<h3>About Verona Pharma</h3>
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Following our analysis of the options activities associated with Verona Pharma, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Verona Pharma</h3>
<ul>
<li>Currently trading with a volume of 1,114,755, the VRNA's price is up by 5.52%, now at $53.09. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 42 days.</li>
</ul>
<h3>Professional Analyst Ratings for Verona Pharma</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $66.33333333333333.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $57. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Verona Pharma with a target price of $74. 
&#x2A; An analyst from Roth MKM downgraded its action to Buy with a price target of $68. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Verona Pharma options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

VRNA

Verona Pharma's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SYM, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Symbotic.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 60%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $30,800, and 9, calls, for a total amount of $382,572.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $32.5 for Symbotic during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Symbotic stands at 912.88, with a total volume reaching 2,364.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Symbotic, situated within the strike price corridor from $20.0 to $32.5, throughout the last 30 days.
<h3>Symbotic Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054972_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.5</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$32.50</td>
<td>$77.1K</td>
<td>1.4K</td>
<td align="right">652</td>
</tr>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$8.7</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$30.00</td>
<td>$48.6K</td>
<td>818</td>
<td align="right">0</td>
</tr>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$15.5</td>
<td>$15.3</td>
<td>$15.5</td>
<td>$22.50</td>
<td>$41.8K</td>
<td>258</td>
<td align="right">27</td>
</tr>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.15</td>
<td>$1.9</td>
<td>$2.07</td>
<td>$30.00</td>
<td>$41.3K</td>
<td>2.9K</td>
<td align="right">571</td>
</tr>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$2.65</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$30.00</td>
<td>$38.5K</td>
<td>1.1K</td>
<td align="right">289</td>
</tr>
</tbody>
</table>

<h3>About Symbotic</h3>
Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys end-to-end technology solutions that dramatically improve supply chain operations. Th company also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.
Having examined the options trading patterns of Symbotic, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Symbotic</h3>
<ul>
<li>Currently trading with a volume of 10,438,753, the SYM's price is up by 20.58%, now at $32.28. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 18 days.</li>
</ul>
<h3>Expert Opinions on Symbotic</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $34.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from DA Davidson upgraded its action to Buy with a price target of $35. 
&#x2A; An analyst from UBS persists with their Neutral rating on Symbotic, maintaining a target price of $32. 
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Buy, setting a price target of $37. 
&#x2A; In a cautious move, an analyst from Oppenheimer downgraded its rating to Outperform, setting a price target of $35. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Symbotic, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Symbotic

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are trading higher Thursday after the prominent short-selling firm Hindenburg Research <a href="https://www.benzinga.com/markets/equities/25/01/43022221/smci-stock-gains-over-3-in-thursday-pre-market-after-short-seller-who-alleged-accounting-manipulation-shuts-shop-nikola-block-and-carvana-also-in-focus">announced its closure</a>.
What To Know: Hindenburg, known for high-profile short reports, accused Super Micro Computer last year of accounting manipulation, sibling self-dealing, and sanctions evasion, triggering significant scrutiny of the company.
The firm, founded in 2017 by Nathan Anderson, gained attention for investigations targeting major companies, including Nikola Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>), India's Adani Group, and Jack Dorsey's Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>). Hindenburg's reports often caused steep stock price drops and legal challenges for its targets. For instance, its 2023 exposé on Adani Group led to a $100 billion market value loss, while its 2020 report on Nikola resulted in the resignation of its founder Trevor Milton.
Hindenburg&#8217;s closure, attributed to personal reasons, potentially marks the end of an influential era in short selling. The firm&#8217;s final report accused Carvana Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) of accounting irregularities, allegations the company denied. 
Anderson plans to document Hindenburg's investigative methods over the next six months, aiming to inspire future market watchdogs and analysts.
SMCI Price Action: Super Micro Computer shares were up 2.3% at $31.68 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16132652/Screenshot-2025-01-16-at-13.22.41-1024x540.png" alt="" class="wp-image-737465" style="width:440px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16132652/Screenshot-2025-01-16-at-13.22.41-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16132652/Screenshot-2025-01-16-at-13.22.41-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16132652/Screenshot-2025-01-16-at-13.22.41-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16132652/Screenshot-2025-01-16-at-13.22.41.png 1530w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/01/43036258/polar-vortex-brings-winters-coldest-air-for-trumps-inauguration-day-what-it-means-for-utilities-retailers-energy-stocks">Polar Vortex Brings Winter&#8217;s Coldest Air For Trump&#8217;s Inauguration Day: What It Means For Utilities, Retailers, Energy Stocks</a></li>
</ul>
Image Via Shutterstock.

News

Movers

CVNA

NKLA

SMCI

Super Micro Computer Shares Are On The Rise: What's Going On?

Keefe, Bruyette &amp; Woods analyst Aidan Hall raised the price forecast on BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) to $1,180 from $1,160 <a target="_blank" href="https://www.benzinga.com/quote/blk/analyst-ratings" rel="noreferrer noopener">while maintaining an Outperform rating</a>.
On Wednesday, the investment giant&nbsp;reported fourth-quarter results, with revenue of&nbsp;$5.68 billion, beating the consensus of&nbsp;$5.53 billion and adjusted EPS of $11.93,&nbsp;<a target="_blank" href="https://www.benzinga.com//node/42997625" rel="noreferrer noopener">surpassing the consensus of&nbsp;$11.21</a>.
The analyst writes that BLK shares responded favorably to the results, surpassing both peers and the broader market by more than 300 basis points.
BlackRock is still in the early phases of its transformation, with management&#8217;s commentary remaining constructive on growth initiatives for 2025, adds the analyst.
Notably, Hall writes that management highlighted ongoing initiatives to meet the growing demand for alternative investments in the retail channel.
These include a managed model partnership with Partners Group, offering a single-subscription document with three risk profiles and a mix of BlackRock and Partners Group funds, adds the analyst.
Also, the analyst writes that management expects core G&amp;A growth in the mid-to-high single digits for 2025, including expenses related to GIP and Preqin.
Hall now anticipates $152.5 million in G&amp;A expenses from GIP and Preqin and expects core G&amp;A to grow 7.9% in 2025, excluding HPS, which the analyst model to close by June 30.
Management also expects continued operating margin expansion, driven by a more variable expense base, with the analyst projecting an estimated 80bps margin improvement to 45.3% in 2025.
Consequently, the analyst slightly adjusted EPS estimates to $10.94 (from $10.92) for first-quarter FY25, $47.23 (from $46.94) for 2025 and $53.62 (from $53.89) for 2026.
The revisions reflect higher operating expenses, primarily from compensation and benefits, as well as amortization of intangibles, partially offset by higher total revenue, says the analyst.
Investors can gain exposure to the stock via&nbsp;Fidelity Disruptive Finance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>) and Spinnaker ETF Series Genter Capital International Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENW#NYSE">GENW</a>).
Price Action: BLK shares are down 2.44% at $988.42 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43027627" target="_blank" rel="noreferrer noopener">BlackRock&#8217;s ETF Business Excels In 2024 With Record $390 Billion Net Inflows</a></li>
</ul>
Photo by rafapress on Shutterstock.

Analyst Color

Equities

Large Cap

Price Target

Reiteration

Analyst Ratings

Trading Ideas

FDFF

GENW

BlackRock Warrants Premium Valuation, Analyst Highlights Growth Potential And Initiatives

Citigroup Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) reported a <a href="https://www.benzinga.com/news/buybacks/25/01/43002760/citigroup-q4-earnings-12-topline-growth-2-9-billion-net-income-20-billion-share-buyback-gains-in-wealth-and-market-segments" target="_blank" rel="noreferrer noopener">fourth-quarter fiscal 2024</a> revenue growth of 12% to $19.58 billion, topping the analyst consensus estimate of $19.48 billion. 
Earnings per share, or EPS, of $1.34 beat the analyst consensus estimate of $1.22.
The board also approved a new, multi-year $20 billion share buyback program. Now the bank expects a fiscal 2025 revenue of $83.5 billion to $84.5 billion, above the consensus estimate of $83.2 billion. Here&#8217;s how analysts reacted:
<ul>
<li>Goldman Sachs analyst Richard Ramsden maintained Citigroup with a Buy and raised the <a target="_blank" href="https://www.benzinga.com/quote/C/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$77&nbsp;to&nbsp;$86</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst David Konrad reiterated Citigroup with an Outperform and raised the price target from&nbsp;$85&nbsp;to&nbsp;$92.</li>
<li>Truist analyst John McDonald assigned a Buy rating to Citigroup.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/earnings/25/01/43026092/bank-of-america-q4-earnings-6-7-billion-profit-1-7-billion-in-investment-banking-fees-forecasts-higher-nii-in-2025" target="_blank" rel="noreferrer noopener">Bank of America Q4 Earnings: $6.7 Billion Profit, $1.7 Billion In Investment Banking Fees</a>
Goldman Sachs: Citi managed to deliver about 3.5% revenue growth, decline in expense, and increasing buyback in 2024. The stock reaction reflects management&#8217;s outlook reassuring continued improvement in ROTCE in the coming years, supported by the buyback, decline in expense from the current run rate and positive operating leverage through 2026, and unchanged revenue growth profile even with the expense initiatives, which Ramsden estimates to grow roughly 4% in 2025 and 2026.
While management cut its ROTCE target by 100bps to 10%-11%, Ramsden noted that the market was not expecting Citi to reach the high end of its target by 2026. Management reiterated that return improvements will continue into 2027 and beyond. Ramsden now expects Citi to generate ROTCEs of 8.7% in 2025 and 10.5% in 2026.
Keefe, Bruyette &amp; Woods: It was a solid quarter for Citi with a revenue beat driven by net interest income (NII), which included more significant than expected trading NII results. The stock was strong following the results, outperforming the KBW Nasdaq Bank Index (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKX#NASDAQ">BKX</a>) by 240bps, as the 2025 guidance was better than feared. Management did lower its 2026 ROTCE outlook from 11% to a range of 10% to 11% owing to higher franchise investments; however, the consensus was below the low point of this range, and it may provide a more visible glide path.
Although Citi&#8217;s stock has been historically cheap, Konrad noted that near-term catalysts make the stock more attractive. First, Citi is well positioned with its franchise, and recent management changes position the firm to capture revenue opportunities in investment banking and trading, given expectations for improved market conditions following the election, particularly in M&amp;A, ECM, and FICC trading. Second, decreasing regulations could ease some control and procedure risks for Citi and provide meaningful capital relief.
Importantly, Konrad expects buybacks to accelerate, with a potential further acceleration should Basel III Endgame be meaningfully watered down. Given Citi&#8217;s Below-Tangible Book Value (TBV)&nbsp;valuation, this could be a strong catalyst for Citi.
The price target represents 9.8 times Konrad&#8217;s 2026E EPS. The analyst noted his price target is sensitive to changes in the macro environment, including interest rates, credit quality, and company-specific operations.
Truist: Citi lowers its 2026 ROTCE target to 10%-11% and guides 2025 revenues +3%-4% YoY to $83.5 billion-84.5 billion, ahead of consensus at $83.3 billion. Expenses for 2025 are guided down to &#8220;slightly lower than ~$53.8 billion&#8221; versus consensus at $53.4 billion. 
Citi also announced a new $20 billion share repurchase authorization, and its $2.1 billion buyback in the fourth quarter of 2024 was ahead of consensus expectations. The fourth-quarter EPS of $1.34 was beat on the quarter versus the $1.23 consensus. 
The price target is based on 9.1 times McDonald&#8217;s 2026E EPS estimate of $9.30, which assumes a below-peer multiple and reflects Citi&#8217;s inconsistent past execution on prior transformation initiatives and the need to build credibility with the Street.
Price Action: Citigroup stock is down 0.17% at $78.15 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42983278/google-stock-boosted-by-ai-growth-cloud-expansion-and-cost-discipline-despite-doj-and-generative-ai-challenges-analyst" target="_blank" rel="noreferrer noopener">Google Stock Boosted By AI Growth, Cloud Expansion, Cost Discipline Despite DOJ And Generative AI Challenges: Analyst</a></li>
</ul>
Image: Shutterstock

Citi Outperforms Analyst Expectations With 12% Revenue Growth, Confirms $20 Billion Buyback Plan

LUXH

LuxUrban Says Transition To OTC Will Reduce Costs, Fuel Hotel Asset Expansion; Achieved Cash Flow Positivity Dec 2024, Aims For Profitability 2025; Enhances Guest Experience, Strategic Asset Acquisitions To Boost Market Presence

Citigroup analyst Paul Diamond maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Buy and raises the price target from $115 to $125.

Citigroup Maintains Buy on Expand Energy, Raises Price Target to $125

In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), defending its stance that the company&#8217;s proposed fertility services program would breach anti-kickback laws. The program is tied to Vertex&#8217;s gene-editing therapy Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia.
Vertex&nbsp;<a href="https://assets.bwbx.io/documents/users/iqjWHBFdfxIU/rnMCje2Jspgw/v0" target="_blank" rel="noreferrer noopener">sued</a>&nbsp;the HHS in July 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program" rel="noreferrer noopener">FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program</a>
The gene-editing treatment requires high-dose chemotherapy to clear stem cells from the bone marrow, often causing severe side effects, including infertility. To support patients, Vertex provides financial assistance for fertility preservation options like freezing eggs, embryos or reproductive tissues.
Last year, the HHS Office of Inspector General (OIG) confirmed its decision that it could not issue a favorable advisory opinion. According to OIG, the program implicates the anti-kickback statute, poses more than a low risk of fraud and abuse, and does not promote access to gene therapy care.
Also Read: <a href="https://www.benzinga.com/25/01/42987342/vertex-pharmaceuticals-sets-sights-on-expanding-portfolio-with-alyftrek-approval-pain-treatment-progress-and-diabetes-trials" target="_blank" rel="noreferrer noopener">Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials</a>
The biotech challenged this allegation, "the Fertility Preservation Program would not improperly skew medical decision-making or provide an improper inducement to prescribe," nor would it persuade patients to "undergo treatment with Casgevy in exchange for the Fertility Preservation Program."
Endpoints <a target="_blank" href="https://endpts.com/wp-content/uploads/2025/01/show_temp.pdf" rel="noreferrer noopener">published</a> a copy of the lawsuit online Wednesday.
HHS laid out several arguments, claiming Vertex's attempts to &#8220;twist the statute's meaning&#8221; and that the biotech is "grasping at straws&#8230;"
"The point is that Vertex's offer of fertility treatment in exchange for purchasing its product, and only its product, is meant to induce patients to choose that product when they otherwise might not. That is a quintessential quid pro quo," the HHS said.
"Vertex is not offering $70,000 to any sickle cell patient who undergoes myeloablative conditioning to prepare for treatment, regardless whether that patient elects to purchase Vertex's product, or its competitor's similar gene-therapy product, or a bone- and blood-marrow transplant," the HHS wrote. "Vertex is only offering payments on behalf of patients who select its own product."
&#8220;Vertex then posits that its $70,000 offer will not interfere with or skew clinical decisionmaking because fertility services "benefit a patient's quality of life," HHS noted.
&#8220;This is nonsensical. Many offers of remuneration would enhance patient quality of life, but that doesn't render them lawful," the HHS added.
VRTX Price Action: Vertex stock is down 1.41% at $418.29 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43036259/canadian-national-railways-valuation-is-an-opportunity-analyst-shifts-to-bullish-outlook" target="_blank" rel="noreferrer noopener">Canadian National Railway&#8217;s Valuation Is An Opportunity, Analyst Shifts To Bullish Outlook</a></li>
</ul>
Photo: Courtesy Vertex Pharmaceuticals

Biotech

Government

Health Care

Legal

General

VRTX

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'

Citigroup analyst Alicia Yap maintains iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) with a Buy and lowers the price target from $3 to $2.8.

Citigroup Maintains Buy on iQIYI, Lowers Price Target to $2.8

ORCL

SNAP

Billionaire Frank McCourt Says He Is Open To TikTok's Founder And Original Investors Remaining Involved Following Any Deal To Acquire The Co's U.S. Operation

Citigroup analyst Steven Enders maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Neutral and lowers the price target from $287 to $270.

WDAY

Citigroup Maintains Neutral on Workday, Lowers Price Target to $270

<a href="https://www.sportsbookreview.com/news/light-wonder-partner-penn-entertainment-new-product-jan-16-2024/">https://www.sportsbookreview.com/news/light-wonder-partner-penn-entertainment-new-product-jan-16-2024/</a>
It may not be the parent company of one of our&nbsp;<a href="https://www.sportsbookreview.com/betting-sites/">best sports betting sites</a>, but PENN Entertainment is certainly doing its best to make moves to continue to make a name for itself and promote growth.
The iGaming group Light &amp; Wonder has announced that it is launching its new player engagement product portfolio on PENN Entertainment's online Hollywood Casino platform in the&nbsp;<a href="https://www.sportsbookreview.com/casino/us/michigan/">Michigan online casino</a>&nbsp;market.

PENN

Light & Wonder Partner With PENN Entertainment To Launch New Product, A New Player Engagement Product Portfolio On PENN Entertainment's Online Hollywood Casino Platform In The Michigan Online Casino Market

Citigroup analyst Steven Enders maintains Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with a Neutral and raises the price target from $21 to $22.5.

PYCR

Citigroup Maintains Neutral on Paycor HCM, Raises Price Target to $22.5

Citigroup analyst Steven Enders maintains Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) with a Neutral and lowers the price target from $234 to $221.

PAYC

Citigroup Maintains Neutral on Paycom Software, Lowers Price Target to $221

Citigroup analyst Steven Enders maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $33 to $30.

OTEX

Citigroup Maintains Neutral on Open Text, Lowers Price Target to $30

Financial giants have made a conspicuous bearish move on Duolingo. Our analysis of options history for Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $108,187, and 6 were calls, valued at $405,960.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $390.0 for Duolingo during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Duolingo's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Duolingo's significant trades, within a strike price range of $250.0 to $390.0, over the past month.
<h3>Duolingo Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054071_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$112.8</td>
<td>$111.3</td>
<td>$111.7</td>
<td>$250.00</td>
<td>$122.8K</td>
<td align="right">7</td>
<td align="right">11</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$71.9</td>
<td>$68.9</td>
<td>$70.5</td>
<td>$300.00</td>
<td>$91.6K</td>
<td align="right">26</td>
<td align="right">13</td>
</tr>
<tr>
<td>DUOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$18.0</td>
<td>$17.4</td>
<td>$18.0</td>
<td>$350.00</td>
<td>$82.6K</td>
<td align="right">13</td>
<td align="right">49</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$9.5</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$390.00</td>
<td>$73.7K</td>
<td align="right">32</td>
<td align="right">89</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$93.5</td>
<td>$92.4</td>
<td>$92.4</td>
<td>$330.00</td>
<td>$46.2K</td>
<td align="right">9</td>
<td align="right">6</td>
</tr>
</tbody>
</table>

<h3>About Duolingo</h3>
Duolingo Inc is a technology company that develops mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include The Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has three predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test.
Having examined the options trading patterns of Duolingo, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Duolingo</h3>
<ul>
<li>With a volume of 645,532, the price of DUOL is up 7.98% at $345.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>Expert Opinions on Duolingo</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $385.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Duolingo, which currently sits at a price target of $385. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Duolingo with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DUOL

Smart Money Is Betting Big In DUOL Options

Investors with a lot of money to spend have taken a bearish stance on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Astera Labs.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 63%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $733,028, and 5 are calls, for a total amount of $338,840.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $150.0 for Astera Labs during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Astera Labs's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale activity within a strike price range from $100.0 to $150.0 in the last 30 days. 
<h3>Astera Labs 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054065_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$23.9</td>
<td>$23.2</td>
<td>$23.9</td>
<td>$125.00</td>
<td>$239.0K</td>
<td>29</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$16.3</td>
<td>$15.7</td>
<td>$16.3</td>
<td>$110.00</td>
<td>$163.0K</td>
<td>188</td>
<td align="right">0</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$16.3</td>
<td>$15.6</td>
<td>$16.3</td>
<td>$110.00</td>
<td>$163.0K</td>
<td>188</td>
<td align="right">200</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$12.7</td>
<td>$11.4</td>
<td>$11.52</td>
<td>$130.00</td>
<td>$115.7K</td>
<td>1.8K</td>
<td align="right">131</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$11.6</td>
<td>$10.8</td>
<td>$11.12</td>
<td>$140.00</td>
<td>$109.5K</td>
<td>527</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Astera Labs</h3>
Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.
Following our analysis of the options activities associated with Astera Labs, we pivot to a closer look at the company's own performance.
<h3>Where Is Astera Labs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,217,628, the ALAB's price is down by -5.91%, now at $123.98. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 25 days.</li>
</ul>
<h3>Expert Opinions on Astera Labs</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $137.33333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Northland Capital Markets downgraded its rating to Market Perform, setting a price target of $120. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Astera Labs, maintaining a target price of $142. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Astera Labs, which currently sits at a price target of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Astera Labs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ALAB

Decoding Astera Labs's Options Activity: What's the Big Picture?

Throughout the last three months, 11 analysts have evaluated DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, a high estimate of $115.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 2.73% increase from the previous average price target of $93.36.
<img src="https://www.benzinga.com/files/images/story/2025/1737054064_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>All You Need to Know About DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Financial Insights: DexCom</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 1.97% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.31, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

Expert Outlook: DexCom Through The Eyes Of 11 Analysts

Investors with a lot of money to spend have taken a bullish stance on American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXP, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 16 options trades for American Express.
This isn't normal.
The overall sentiment of these big-money traders is split between 43% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $98,600, and 15, calls, for a total amount of $1,345,104.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $320.0 for American Express over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for American Express's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of American Express's whale activity within a strike price range from $160.0 to $320.0 in the last 30 days. 
<h3>American Express 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054060_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$37.8</td>
<td>$36.95</td>
<td>$37.7</td>
<td>$290.00</td>
<td>$754.0K</td>
<td align="right">906</td>
<td align="right">10</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$154.0</td>
<td>$152.4</td>
<td>$154.0</td>
<td>$160.00</td>
<td>$154.0K</td>
<td align="right">104</td>
<td align="right">10</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$17.0</td>
<td>$16.55</td>
<td>$17.0</td>
<td>$320.00</td>
<td>$98.6K</td>
<td align="right">100</td>
<td align="right">61</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$16.3</td>
<td>$15.7</td>
<td>$16.3</td>
<td>$310.00</td>
<td>$55.4K</td>
<td align="right">943</td>
<td align="right">40</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$5.1</td>
<td>$4.65</td>
<td>$5.1</td>
<td>$320.00</td>
<td>$50.4K</td>
<td align="right">139</td>
<td align="right">116</td>
</tr>
</tbody>
</table>

<h3>About American Express</h3>
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
Having examined the options trading patterns of American Express, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is American Express Standing Right Now?</h3>
<ul>
<li>With a volume of 1,175,128, the price of AXP is down -0.31% at $311.34. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>Professional Analyst Ratings for American Express</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $321.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Neutral rating on American Express, maintaining a target price of $320. 
&#x2A; Consistent in their evaluation, an analyst from Compass Point keeps a Neutral rating on American Express with a target price of $325. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on American Express, maintaining a target price of $305. 
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $350. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for American Express, targeting a price of $307. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for American Express, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

American Express's Options: A Look at What the Big Money is Thinking

During the last three months, 10 analysts shared their evaluations of Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $182.3, a high estimate of $209.00, and a low estimate of $160.00. This current average has increased by 2.99% from the previous average price target of $177.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737054054_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Procter &amp; Gamble by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$209.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$209.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$164.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$159.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Procter &amp; Gamble. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Procter &amp; Gamble's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Procter &amp; Gamble's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Procter &amp; Gamble analyst ratings.</a>
<h2>All You Need to Know About Procter &amp; Gamble</h2>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
<h3>Key Indicators: Procter &amp; Gamble's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Procter &amp; Gamble's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -0.61%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Procter &amp; Gamble's net margin excels beyond industry benchmarks, reaching 17.88%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Procter &amp; Gamble's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 7.73%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.12%, the company showcases effective utilization of assets.
Debt Management: Procter &amp; Gamble's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.71.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Coeur D'Alene Bancorp

Coeur D'Alene Bancorp (CDAB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO